Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ritlecitinib in Moderate to Severe Hidradenitis Suppurativa
NCT07228390Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of ritlecitinib tosilate in hidradenitis suppurativa (HS), sponsored by Pfizer. Started Nov 2025; status: active, not recruiting.
02
Drugs
ritlecitinib tosilate
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT07228390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07228390.